Press Release Details

Investor Relations

GoHealth Reports Second Quarter 2021 Results

Aug 11, 2021 at 4:05 PM EDT
Revises Full Year 2021 Growth Outlook

CHICAGO, Aug. 11, 2021 /PRNewswire/ -- GoHealth, Inc. (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced financial results for the three and six months ended June 30, 2021.

  • Second quarter 2021 net revenue of $196.9 million increased 55% compared to the prior year period. YTD 2021 net revenue of $401.1 million increased 50% compared to the prior year period.
  • Second quarter 2021 Medicare—Internal revenue of $160.4 million increased 84% compared to the prior year period. YTD 2021 Medicare—Internal revenue of $317.8 million increased 74% compared to the prior year period.
  • Second quarter 2021 Medicare Advantage ("MA") Approved Submissions of 152,749 increased 58% compared to the prior year period. YTD 2021 MA Approved Submissions of 323,876 increased 52% compared to the prior year period.
  • Second quarter 2021 MA LTV Per Approved Submission of $953 increased 5% compared to the prior year period. YTD 2021 MA LTV Per Approved Submission of $975 increased 11% compared to the prior year period.
  • Second quarter 2021 net loss of $39.2 million compared to a net loss of $22.9 million in the prior year period; Adjusted EBITDA1 of $14.3 million decreased 47% compared to the prior year period due to the 2021 strategic investments in agent capacity, marketplace technology, branding and the Encompass Platform. YTD 2021 net loss was $46.4 million compared to a net loss of $23.8 million in the prior year period; Adjusted EBITDA1 of $46.4 million decreased 25% compared to the prior year period.
  • The Company tightened its full year 2021 revenue outlook to $1,200 - $1,300 million (+37% to +48%) powered by commission net revenue of $1,000 - $1,100 million (+49% to +64%) as agent growth is tracking at the high end of expectations. The Company lowered its Adjusted EBITDA1 outlook to $300 - $330 million (+11% to +22%), primarily due to higher agent costs expected in 2021.

Clint Jones, co-founder and CEO said, "GoHealth's second quarter revenue growth of 55% was driven by an 84% gain in our Medicare—Internal segment with LTVs expanding 5%. Our ramped up investments in our Encompass Platform led to $17 million in revenue contribution from the platform's additional services beyond enrollment for carriers. Given the 50% top-line growth over the first six months and continued strength in the market, we have raised and tightened our revenue expectations for full year fiscal 2021."

Jones continued, "These excellent top-line results are enabled by our success at increasing our agent counts ahead of the 50% growth target, ensuring that we have ample agent capacity to address the anticipated demand during this year's Annual Enrollment Period. While we are encouraged by the growth in our agent force, enhanced training and tight labor markets have created cost pressures that we expect to continue over the balance of the year. Given these higher agent costs, we are reducing our outlook for 2021 Adjusted EBITDA. We anticipate that these 2021 investments in agents, training, technology and Encompass will position us well for continued strong efficient growth in 2022."

Second Quarter 2021 Highlights2

  • Total company revenue grew 55% to $196.9 million
    • Total Medicare Commissionable Submitted Policies grew 52% to 156,559
  • Medicare—Internal net revenue increased 84% to $160.4 million
  • LTV Per carrier Approved MA Submission increased 5% to $953
  • Adjusted EBITDA1 decreased 47% to $14.3 million
    • Aggregate investment in customer care and enrollment and technology grew $39.8 million to $73.9 million, an increase of 117%, including enhanced tools and training to continue powering conversion gains and improved effectuation, as well as investments in the Encompass platform
      • Agent counts grew well ahead of the 50% target as the Company prepares for the Annual Enrollment Period and fiscal 2022
    • Total cost of revenue, marketing and advertising expense grew 60%, roughly in line with sales growth
  • The Company refinanced a portion of its term loans, upsized its revolver to $200 million, and lowered its annual borrowing costs by over $7 million
 

YTD 2021 Highlights2

  • Total company revenue grew 50% to $401.1 million
    • Total Medicare Commissionable Submitted Policies grew 48% to 333,130
  • Medicare—Internal net revenue increased 74% to $317.8 million
    • Medicare—Internal segment profit increased 4% to $77.7 million
  • LTV Per carrier Approved MA Submission increased 11% to $975
  • Adjusted EBITDA1 decreased 25% to $46.4 million
    • Aggregate investment in customer care and enrollment and technology grew 108% to $68.0 million
    • Total cost of revenue, marketing and advertising expense grew 55%, roughly in line with sales growth
 

2021 Financial Outlook

The trajectory of the U.S. economy remains challenging to predict, particularly given the continued uncertainty associated with the pace of recovery from the COVID-19 pandemic. The Company is revising its financial outlook for the fiscal year ending December 31, 2021 based on current market conditions and expectations:

  • Full-year 2021 net revenue of $1,200 - $1,300 million, representing year-over-year growth of 37% - 48%
    • Full-year 2021 commission revenue of $1,000 - $1,100 million, representing year-over-year growth of 49% - 64%, fueled by the Company's continued investment in its Medicare business, including GoHealth's Encompass Platform
  • Full-year 2021 Adjusted EBITDA1 of $300 - $330 million, representing year-over-year growth of 11% - 22%

Jones added, "Seniors continue to demonstrate a high degree of interest in our model, and increasingly want to explore their Medicare plan choices from the safety and comfort of their own home through our Choice platform. GoHealth's telesales agents are equipped with the decision support tools and experience to help consumers select the right plan for their unique needs and achieve a superior health outcome with lower costs. We are in the early days of realizing this enormous market opportunity by building GoHealth's position as the trusted advisor for consumers, helping these consumers navigate their healthcare journey through our Encompass offerings, and in the process, creating value for our carrier partners through driving high-quality enrollments."

Conference Call Details

The Company will host a conference call today, Wednesday, August 11, 2021 at 5:00 p.m. (ET) to discuss its financial results.  A live audio webcast and a supplemental presentation will be available online at https://investors.gohealth.com. The conference call can also be accessed by dialing 1-833-519-1310 for U.S. participants, or 1-914-800-3876 for international participants, and referencing participant code 5464567. A replay of the call will be available for 30 days via webcast for on-demand listening shortly after the completion of the call, at the same web link.

About GoHealth, Inc.:

As a leading health insurance marketplace and Medicare-focused digital health company, GoHealth's mission is to improve access to healthcare in America. Enrolling in a health insurance plan can be confusing for customers, and the seemingly small differences between plans can lead to significant out-of-pocket costs or lack of access to critical medicines and even providers. GoHealth combines cutting-edge technology, data science and deep industry expertise to match customers with the healthcare policy and carrier that is right for them. Since its inception, GoHealth has enrolled millions of people in Medicare and individual and family plans. For more information, visit https://www.gohealth.com.

Investor Relations:
Jay Koval, VP of Investor Relations
IR@gohealth.com  

Media Relations:
Pressinquiries@gohealth.com

 

(1)

Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below.

(2)

Second quarter and YTD 2021 results compared to the comparable prior year period.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding expected financial performance and operational performance for the fiscal year 2021, including with respect to revenue and Adjusted EBITDA are forward-looking statements. In some cases, you can identify forward-looking statements by terms, such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. There are or will be important factors that could cause the Company's actual results to differ materially from those indicated in these forward-looking statements, including, but are not limited to, the following: the Company's ability to comply with the numerous, complex and frequently changing laws regulating the marketing and sale of Medicare plans; the potential for an adverse change in the Company's relationships with carriers, including a loss of a carrier relationship; failure to grow the Company's customer base or retain its existing customers; the time and cost of training agents are significant and can increase during a period of high attrition; carriers' ability to reduce commissions paid to the Company and adversely change their underwriting practices; significant consolidation in the healthcare industry which could adversely alter the Company's relationships with carriers; information technology systems failures or capacity constraints interrupting the Company's operations; factors that adversely impact the Company's estimate of LTV; the Company's dependence on agents to sell insurance plans; changes in the health insurance system and laws and regulation governing health insurance markets; the inability to effectively advertise the Company's products; and our ability to successfully implement our business plan during a global economic downturn caused by the COVID-19 pandemic.

The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and other SEC filings. If one or more events related to these or other risks or uncertainties materialize, or if the Company's underlying assumptions prove to be incorrect, actual results may differ materially from what the Company anticipates. Many of the important factors that will determine these results are beyond the Company's ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, the Company does not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time-to-time, and it is not possible for us to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Use of Non-GAAP Financial Measures and Key Performance Indicators

In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). These non-GAAP financial measures include net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense ("EBITDA"); Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA is the primary financial performance measure used by management to evaluate its business and monitor its results of operations.

Adjusted EBITDA represents EBITDA as further adjusted for share-based compensation, loss on debt extinguishment, non-recurring legal fees, change in fair value of contingent consideration liability, IPO transaction costs, and severance costs. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues.

We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for net income (loss) prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA and Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

Management has provided its outlook regarding Adjusted EBITDA, which is a non-GAAP financial measure and excludes certain charges. Reconciliations of Adjusted EBITDA to its most directly comparable GAAP financial measure, net income (loss), is presented in the table below in this press release.

Glossary

"Adjusted EBITDA" represents, as applicable for the period, EBITDA as further adjusted for share-based compensation expense, loss on extinguishment of debt, non-recurring legal fees, change in fair value of contingent consideration liability, IPO transaction costs, and severance costs.

"Adjusted EBITDA Margin" refers to Adjusted EBITDA divided by net revenues.

"Approved Submissions" refer to Submitted Policies approved by carriers for the identified product during the indicated period.

"LTV Per Approved Submission" refers to the Lifetime Value of Commissions per Approved Submission, which we define as (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Approved Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of commissionable Approved Submissions for such period.

"Revenue Per Submission" refers to the total net revenues per Submitted Policy, which we define as (i) total net revenue, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, divided by (ii) the number of Submitted Policies for such period.

"Submitted Policies" refer to completed applications that, with respect to each such application, the consumer has authorized us to submit to the carrier.

The following tables set forth the components of our results of operations for the periods indicated (unaudited):

(in thousands, except percentages and per share amounts)

 

Three months ended Jun.
30, 2021

 

Three months ended Jun.
30, 2020

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Commission

 

$

147,508

   

74.9

%

 

$

96,606

   

76.0

%

 

$

50,902

   

52.7

%

Enterprise

 

49,394

   

25.1

%

 

30,451

   

24.0

%

 

18,943

   

62.2

%

Net revenues

 

196,902

   

100.0

%

 

127,057

   

100.0

%

 

69,845

   

55.0

%

Operating expenses:

                       

Cost of revenue

 

37,442

   

19.0

%

 

36,559

   

28.8

%

 

883

   

2.4

%

Marketing and advertising

 

55,735

   

28.3

%

 

21,634

   

17.0

%

 

34,101

   

157.6

%

Customer care and enrollment

 

61,927

   

31.5

%

 

28,394

   

22.3

%

 

33,533

   

118.1

%

Technology

 

11,983

   

6.1

%

 

5,705

   

4.5

%

 

6,278

   

110.0

%

General and administrative

 

25,251

   

12.8

%

 

10,359

   

8.2

%

 

14,892

   

143.8

%

Change in fair value of contingent consideration liability

 

   

%

 

15,300

   

12.0

%

 

(15,300)

   

N/M

Amortization of intangible assets

 

23,515

   

11.9

%

 

23,514

   

18.5

%

 

1

   

%

Total operating expenses

 

215,853

   

109.6

%

 

141,465

   

111.3

%

 

74,388

   

52.6

%

Income (loss) from operations

 

(18,951)

   

(9.6)

%

 

(14,408)

   

(11.3)

%

 

(4,543)

   

31.5

%

Interest expense

 

8,277

   

4.2

%

 

8,986

   

7.1

%

 

(709)

   

(7.9)

%

Loss on extinguishment of debt

 

11,935

   

6.1

%

 

   

%

 

11,935

   

N/M

Other (income) expense

 

44

   

%

 

(505)

   

(0.4)

%

 

549

   

N/M

Income (loss) before income taxes

 

(39,207)

   

(19.9)

%

 

(22,889)

   

(18.0)

%

 

(16,318)

   

71.3

%

Income tax expense (benefit)

 

(32)

   

%

 

(22)

   

%

 

(10)

   

N/M

Net income (loss)

 

$

(39,175)

   

(19.9)

%

 

$

(22,867)

   

(18.0)

%

 

$

(16,308)

   

71.3

%

Net income (loss) attributable to noncontrolling interests

 

(27,186)

   

(13.8)

%

               

Net income (loss) attributable to GoHealth, Inc.

 

$

(11,989)

   

(6.1)

%

               

Net income (loss) per share:

                       

Net income (loss) per share of common stock — basic and diluted

 

$

(0.12)

                     

Weighted-average shares of common stock outstanding — basic and diluted

 

102,300

                     

Non-GAAP financial measures:

                       

EBITDA

 

$

(5,192)

       

$

10,615

             

Adjusted EBITDA

 

$

14,342

       

$

26,936

             

Adjusted EBITDA margin

 

7.3

%

     

21.2

%

           

_________________________

NM = Not meaningful

 

(in thousands, except percentages and per share amounts)

 

Six months ended Jun.
30, 2021

 

Six months ended Jun.
30, 2020

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Commission

 

$

321,489

   

80.2

%

 

$

209,116

   

78.0

%

 

$

112,373

   

53.7

%

Enterprise

 

79,592

   

19.8

%

 

58,951

   

22.0

%

 

20,641

   

35.0

%

Net revenues

 

401,081

   

100.0

%

 

268,067

   

100.0

%

 

133,014

   

49.6

%

Operating expenses:

                       

Cost of revenue

 

85,817

   

21.4

%

 

78,693

   

29.4

%

 

7,124

   

9.1

%

Marketing and advertising

 

110,219

   

27.5

%

 

47,708

   

17.8

%

 

62,511

   

131.0

%

Customer care and enrollment

 

109,021

   

27.2

%

 

52,371

   

19.5

%

 

56,650

   

108.2

%

Technology

 

21,600

   

5.4

%

 

10,298

   

3.8

%

 

11,302

   

109.7

%

General and administrative

 

44,944

   

11.2

%

 

20,849

   

7.8

%

 

24,095

   

115.6

%

Change in fair value of contingent consideration liability

 

   

%

 

19,700

   

7.3

%

 

(19,700)

   

N/M

Amortization of intangible assets

 

47,029

   

11.7

%

 

47,029

   

17.5

%

 

   

%

Total operating expenses

 

418,630

   

104.4

%

 

276,648

   

103.2

%

 

141,982

   

51.3

%

Income (loss) from operations

 

(17,549)

   

(4.4)

%

 

(8,581)

   

(3.2)

%

 

(8,968)

   

104.5

%

Interest expense

 

16,965

   

4.2

%

 

15,742

   

5.9

%

 

1,223

   

7.8

%

Loss on extinguishment of debt

 

11,935

   

3.0

%

 

   

%

 

11,935

   

N/M

Other (income) expense

 

57

   

%

 

(495)

   

(0.2)

%

 

552

   

(111.5)

%

Income (loss) before income taxes

 

(46,506)

   

(11.6)

%

 

(23,828)

   

(8.9)

%

 

(22,678)

   

95.2

%

Income tax expense (benefit)

 

(63)

   

%

 

(24)

   

%

 

(39)

   

N/M

Net income (loss)

 

$

(46,443)

   

(11.6)

%

 

$

(23,804)

   

(8.9)

%

 

$

(22,639)

   

95.1

%

Net loss attributable to noncontrolling interests

 

(32,364)

   

(8.1)

%

               

Net loss attributable to GoHealth, Inc.

 

$

(14,079)

   

(3.5)

%

               

Net income (loss) per share:

                       

Net income (loss) per share of common stock — basic and diluted

 

$

(0.14)

                     

Weighted-average shares of common stock outstanding — basic and diluted

 

97,349

                     

Non-GAAP financial measures:

                       

EBITDA

 

$

21,564

       

$

40,579

             

Adjusted EBITDA

 

$

46,390

       

$

61,857

             

Adjusted EBITDA margin

 

11.6

%

     

23.1

%

           

_________________________

NM = Not meaningful

 

 

The following tables set forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):

(in thousands)

 

Three months ended Jun. 30, 2021

 

Three months ended Jun. 30, 2020

Net revenues

 

$

196,902

   

$

127,057

 

Net income (loss)

 

(39,175)

   

(22,867)

 

Interest expense

 

8,277

   

8,986

 

Income tax expense (benefit)

 

(32)

   

(22)

 

Depreciation and amortization expense

 

25,738

   

24,518

 

EBITDA

 

(5,192)

   

10,615

 

Loss on extinguishment of debt (1)

 

11,935

   

 

Share-based compensation expense (2)

 

7,599

   

597

 

Change in fair value of contingent consideration liability (3)

 

   

15,300

 

IPO transaction costs (4)

 

   

424

 

Adjusted EBITDA

 

$

14,342

   

$

26,936

 

Adjusted EBITDA margin

 

7.3

%

 

21.2

%

_________________________

(1)

Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

(2)

Represents non-cash share-based compensation expense relating to equity awards.

(3)

Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

(4)

Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

 

(in thousands)

 

Six months
ended Jun.
30, 2021

 

Six months
ended Jun.
30, 2020

Net revenues

 

$

401,081

   

$

268,067

 

Net income (loss)

 

(46,443)

   

(23,804)

 

Interest expense

 

16,965

   

15,742

 

Income tax expense (benefit)

 

(63)

   

(24)

 

Depreciation and amortization expense

 

51,105

   

48,665

 

EBITDA

 

21,564

   

40,579

 

Loss on extinguishment of debt (1)

 

11,935

   

 

Share-based compensation expense (2)

 

12,711

   

1,077

 

Legal fees (3)

 

180

   

 

Change in fair value of contingent consideration liability (4)

 

   

19,700

 

IPO transaction costs (5)

 

   

424

 

Severance costs (6)

 

   

77

 

Adjusted EBITDA

 

$

46,390

   

$

61,857

 

Adjusted EBITDA margin

 

11.6

%

 

23.1

%

_________________________

(1)

Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

(2)

Represents non-cash share-based compensation expense relating to equity awards.

(3)

Represents non-recurring legal fees unrelated to our core operations.

(4)

Represents the change in fair value of the contingent consideration liability due to the predecessor owners of the Company arising from the Centerbridge Acquisition.

(5)

Represents legal, accounting, consulting, and other indirect costs associated with the Company's IPO.

(6)

Represents costs associated with the termination of employment.

 

 

The following table summarizes share-based compensation expense by operating function for the periods indicated (unaudited):

(in thousands)

 

Three
months
ended Jun.
30, 2021

 

Three
months
ended Jun.
30, 2020

 

Six months
ended Jun.
30, 2021

 

Six months
ended Jun.
30, 2020

Marketing and advertising

 

$

426

   

$

61

   

$

764

   

$

119

 

Customer care and enrollment

 

1,043

   

32

   

1,839

   

58

 

Technology

 

1,133

   

83

   

1,880

   

159

 

General and administrative

 

4,997

   

421

   

8,228

   

741

 

Total share-based compensation expense

 

$

7,599

   

$

597

   

$

12,711

   

$

1,077

 

 

The following table sets forth our balance sheets for the periods indicated (unaudited):

(in thousands, except per share amounts)

 

Jun. 30, 2021

 

Dec. 31, 2020

Assets

       

Current assets:

       

Cash and cash equivalents

 

$

112,863

   

$

144,234

 

Accounts receivable, net of allowance for doubtful accounts of $686 in 2021 and $787 in 2020

 

17,335

   

14,211

 

Receivable from NVX Holdings, Inc.

 

   

3,395

 

Commissions receivable - current

 

113,062

   

188,128

 

Prepaid expense and other current assets

 

52,992

   

41,854

 

Total current assets

 

296,252

   

391,822

 

Commissions receivable - non-current

 

761,011

   

622,270

 

Other long-term assets

 

2,594

   

2,072

 

Property, equipment, and capitalized software, net

 

23,527

   

17,353

 

Intangible assets, net

 

641,697

   

688,726

 

Goodwill

 

386,553

   

386,553

 

Total assets

 

$

2,111,634

   

$

2,108,796

 

Liabilities and Stockholders' Equity

       

Current liabilities:

       

Accounts payable

 

$

17,080

   

$

8,733

 

Accrued liabilities

 

31,036

   

26,926

 

Commissions payable - current

 

51,579

   

78,478

 

Deferred revenue

 

700

   

736

 

Current portion of long-term debt

 

4,270

   

4,170

 

Other current liabilities

 

9,207

   

8,328

 

Total current liabilities

 

113,872

   

127,371

 

Non-current liabilities:

       

Commissions payable - non-current

 

214,237

   

182,596

 

Long-term debt, net of current portion

 

414,908

   

396,400

 

Other non-current liabilities

 

2,817

   

3,274

 

Total non-current liabilities

 

631,962

   

582,270

 

Stockholders' equity:

       

Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 105,318 and 84,196 shares issued and
outstanding at June 30, 2021 and December 31, 2020, respectively.

 

10

   

8

 

Class B common stock – $0.0001 par value; 597,502 and 619,004 shares authorized; 215,495 and 236,997 shares
issued and outstanding at June 30, 2021 and December 31, 2020, respectively.

 

22

   

24

 

Preferred stock – $0.0001 par value; 20,000 shares authorized; no shares issued and outstanding at June 30, 2021 and
December 31, 2020.

 

   

 

Additional paid-in capital

 

503,689

   

399,169

 

Accumulated other comprehensive income (loss)

 

(13)

   

17

 

Accumulated deficit

 

(32,881)

   

(18,802)

 

Total stockholders' equity attributable to GoHealth, Inc.

 

470,827

   

380,416

 

Non-controlling interests

 

894,973

   

1,018,739

 

Total stockholders' equity

 

1,365,800

   

1,399,155

 

Total liabilities and stockholders' equity

 

$

2,111,634

   

$

2,108,796

 

 

The following table sets forth our statements of cash flows for the periods indicated (unaudited):

(in thousands)

 

Six months
ended Jun.
30, 2021

 

Six months
ended Jun.
30, 2020

Operating Activities

       

Net income (loss)

 

$

(46,443)

   

$

(23,804)

 

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

       

Share-based compensation

 

12,711

   

1,077

 

Depreciation and amortization

 

4,076

   

1,636

 

Amortization of intangible assets

 

47,029

   

47,029

 

Amortization of debt discount and issuance costs

 

1,262

   

1,058

 

Change in fair value of contingent consideration

 

   

19,700

 

Loss on extinguishment of debt

 

11,935

   

 

Other non-cash items

 

(884)

   

(458)

 

Changes in assets and liabilities, net of acquisition:

       

Accounts receivable

 

(2,702)

   

12,383

 

Commissions receivable

 

(63,675)

   

(58,709)

 

Prepaid expenses and other assets

 

(11,778)

   

1,794

 

Accounts payable

 

6,114

   

(3,467)

 

Accrued liabilities

 

3,993

   

(7,641)

 

Deferred revenue

 

(36)

   

(14,171)

 

Commissions payable

 

4,742

   

18,135

 

Other liabilities

 

1,406

   

1,269

 

Net cash provided by (used in) operating activities

 

(32,250)

   

(4,169)

 

Investing Activities

       

Purchases of property, equipment and software

 

(7,909)

   

(7,764)

 

Net cash provided by (used in) investing activities

 

(7,909)

   

(7,764)

 

Financing Activities

       

Proceeds received upon issuance of common units

 

   

10,000

 

Borrowings under term loans

 

310,000

   

117,000

 

Payments of term loans

 

(296,835)

   

(1,793)

 

Call premium paid for debt extinguishment

 

(5,910)

   

 

Payment of deferred offering costs

 

   

(874)

 

Debt issuance cost payments

 

(1,608)

   

(6,289)

 

Principal payments under capital lease obligations

 

(154)

   

(144)

 

Cash received on advancement to NVX Holdings, Inc.

 

3,395

   

 

Net cash provided by (used in) financing activities

 

8,888

   

117,900

 

Effect of exchange rate changes on cash and cash equivalents

 

(100)

   

98

 

Increase in cash and cash equivalents

 

(31,371)

   

106,065

 

Cash and cash equivalents at beginning of period

 

144,234

   

12,276

 

Cash and cash equivalents at end of period

 

$

112,863

   

$

118,341

 

Supplemental Disclosure of Cash Flow Information

       

Non-cash investing and financing activities:

       

Purchases of property, equipment and software included in accounts payable

 

$

2,233

   

$

798

 

Issuance of senior preferred earnout units to settle contingent consideration liability

 

$

   

$

100,000

 

Issuance of common A and B units to settle contingent consideration liability

 

$

   

$

100,000

 

 

The following tables set forth operating segment results for the periods indicated (unaudited):

(in thousands, except percentages)

 

Three months ended Jun.
30, 2021

 

Three months ended Jun.
30, 2020

       
 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Medicare - Internal

 

$

160,433

   

81.5

%

 

$

87,201

   

68.7

%

 

$

73,232

   

84.0

%

Medicare - External

 

31,379

   

15.9

%

 

28,108

   

22.1

%

 

3,271

   

11.6

%

IFP and Other - Internal

 

3,788

   

1.9

%

 

7,019

   

5.5

%

 

(3,231)

   

(46.0)

%

IFP and Other - External

 

1,302

   

0.7

%

 

4,729

   

3.7

%

 

(3,427)

   

(72.5)

%

Net revenues

 

196,902

   

100.0

%

 

127,057

   

100.0

%

 

69,845

   

55.0

%

Segment profit (loss):

                       

Medicare - Internal

 

31,257

   

15.9

%

 

32,746

   

25.8

%

 

(1,489)

   

(4.5)

%

Medicare - External

 

(1,688)

   

(0.9)

%

 

495

   

0.4

%

 

(2,183)

   

N/M

IFP and Other - Internal

 

(800)

   

(0.4)

%

 

(54)

   

%

 

(746)

   

N/M

IFP and Other - External

 

(57)

   

%

 

130

   

0.1

%

 

(187)

   

(143.8)

%

Segment profit

 

28,712

   

14.6

%

 

33,317

   

26.2

%

 

(4,605)

   

(13.8)

%

Corporate expense

 

24,148

   

12.3

%

 

8,911

   

7.0

%

 

15,237

   

171.0

%

Change in fair value of contingent consideration liability

 

   

%

 

15,300

   

12.0

%

 

(15,300)

   

N/M

Amortization of intangible assets

 

23,515

   

11.9

%

 

23,514

   

18.5

%

 

1

   

%

Loss on extinguishment of debt

 

11,935

   

6.1

%

 

   

%

 

11,935

   

N/M

Interest expense

 

8,277

   

4.2

%

 

8,986

   

7.1

%

 

(709)

   

(7.9)

%

Other (income) expense

 

44

   

%

 

(505)

   

(0.4)

%

 

549

   

N/M

Income (loss) before income taxes

 

$

(39,207)

   

(19.9)

%

 

$

(22,889)

   

(18.0)

%

 

$

(16,318)

   

71.3

%

_________________________

NM = Not meaningful

 

 

   

Six months ended Jun. 30,
2021

 

Six months ended Jun.
30, 2020

       

(in thousands, except percentages)

 

Dollars

 

% of Net
Revenues

 

Dollars

 

% of Net
Revenues

 

$ Change

 

% Change

Net revenues:

                       

Medicare - Internal

 

$

317,786

   

79.2

%

 

$

182,488

   

68.1

%

 

$

135,298

   

74.1

%

Medicare - External

 

70,879

   

17.7

%

 

57,053

   

21.3

%

 

13,826

   

24.2

%

IFP and Other - Internal

 

7,763

   

1.9

%

 

15,651

   

5.8

%

 

(7,888)

   

(50.4)

%

IFP and Other - External

 

4,653

   

1.2

%

 

12,875

   

4.8

%

 

(8,222)

   

(63.9)

%

Net revenues

 

401,081

   

100.0

%

 

268,067

   

100.0

%

 

133,014

   

49.6

%

Segment profit:

                       

Medicare - Internal

 

77,700

   

19.4

%

 

74,482

   

27.8

%

 

3,218

   

4.3

%

Medicare - External

 

(2,319)

   

(0.6)

%

 

173

   

0.1

%

 

(2,492)

   

N/M

IFP and Other - Internal

 

(1,529)

   

(0.4)

%

 

427

   

0.2

%

 

(1,956)

   

N/M

IFP and Other - External

 

103

   

%

 

642

   

0.2

%

 

(539)

   

(84.0)

%

Segment profit

 

73,955

   

18.4

%

 

75,724

   

28.2

%

 

(1,769)

   

(2.3)

%

Corporate expense

 

44,475

   

11.1

%

 

17,576

   

6.6

%

 

26,899

   

153.0

%

Change in fair value of contingent consideration liability

 

   

%

 

19,700

   

7.3

%

 

(19,700)

   

N/M

Amortization of intangible assets

 

47,029

   

11.7

%

 

47,029

   

17.5

%

 

   

%

Loss on extinguishment of debt

 

11,935

   

3.0

%

 

   

%

 

11,935

   

N/M

Interest expense

 

16,965

   

4.2

%

 

15,742

   

5.9

%

 

1,223

   

7.8

%

Other (income) expense

 

57

   

%

 

(495)

   

(0.2)

%

 

552

   

N/M

Income (loss) before income taxes

 

$

(46,506)

   

(11.6)

%

 

$

(23,828)

   

(8.9)

%

 

$

(22,678)

   

95.2

%

_________________________

NM = Not meaningful

 

 

The following table presents the number of Submitted Policies by product for the Medicare segments for the three and six months ended June 30, 2021 and 2020, for those submissions that are commissionable (compensated through commissions received from carriers):

Medicare - Total Commissionable Submitted Policies

 

Three
months
ended Jun.
30, 2021

 

Three
months
ended Jun. 30,
2020

 

Six months
ended Jun.
30, 2021

 

Six months
ended Jun.
30, 2020

Medicare Advantage

 

153,163

 

99,078

 

326,037

 

216,413

Medicare Supplement

 

1,022

 

2,248

 

2,126

 

4,919

Prescription Drug Plans

 

2,374

 

1,969

 

4,967

 

4,431

Total Medicare

 

156,559

 

103,295

 

333,130

 

225,763

 

The following tables present the number of Approved Submissions by product relating to commissionable policies for the Medicare segments for three and six months ended June 30, 2021 and 2020. Only commissionable policies are used to calculate LTV.

Medicare - Internal Commissionable Approved Submissions

 

Three
months
ended Jun.
30, 2021

 

Three
months
ended Jun.
30, 2020

 

Six months
ended Jun.
30, 2021

 

Six months
ended Jun.
30, 2020

Medicare Advantage

 

121,299

 

67,818

 

250,185

 

151,426

Medicare Supplement

 

268

 

465

 

519

 

1,287

Prescription Drug Plans

 

2,033

 

1,571

 

4,317

 

3,745

Total Medicare

 

123,600

 

69,854

 

255,021

 

156,458

 

Medicare - External Commissionable Approved Submissions

 

Three
months
ended Jun.
30, 2021

 

Three
months
ended Jun.
30, 2020

 

Six months
ended Jun.
30, 2021

 

Six months
ended Jun.
30, 2020

Medicare Advantage

 

31,450

 

28,979

 

73,691

 

61,266

Medicare Supplement

 

665

 

1,633

 

1,396

 

3,191

Prescription Drug Plans

 

236

 

405

 

525

 

854

Total Medicare

 

32,351

 

31,017

 

75,612

 

65,311

 

The following table presents the LTV per Approved Submission by product for the Medicare segments for the three and six months ended June 30, 2021 and 2020:

LTV per Approved Submission

 

Three
months
ended Jun.
30, 2021

 

Three
months
ended Jun.
30, 2020

 

Six months
ended Jun.
30, 2021

 

Six months
ended Jun.
30, 2020

Medicare Advantage

 

$

953

 

$

905

 

$

975

 

$

877

Medicare Supplement

 

$

846

 

$

937

 

$

821

 

$

928

Prescription Drug Plans

 

$

215

 

$

215

 

$

215

 

$

216

 

The following table presents the number of Submitted Policies by product for the Medicare segments for the three and six months ended June 30, 2021 and 2020, for those submissions that are non-commissionable (compensated via hourly fees and enrollment fees) and do not result in commission revenue:

Medicare - Total Non-Commissionable Submitted Policies

 

Three
months
ended Jun.
30, 2021

 

Three
months
ended Jun.
30, 2020

 

Six months
ended Jun.
30, 2021

 

Six months
ended Jun.
30, 2020

Medicare Advantage

 

3,232

 

7,407

 

9,171

 

14,334

Medicare Supplement

 

2,042

 

1,734

 

3,692

 

3,546

Prescription Drug Plans

 

791

 

955

 

1,676

 

1,753

Total Medicare

 

6,065

 

10,096

 

14,539

 

19,633

 

The following table presents a reconciliation from net income to non-GAAP Adjusted EBITDA guidance for the twelve months ended December 31, 2021:

   

Twelve months ended

Dec. 31, 2021

   

Guidance Range

(in thousands)

 

Low

 

High

Net revenues

 

$

1,200,000

   

$

1,300,000

 

Net income

 

127,665

   

157,665

 

Interest expense

 

30,000

   

30,000

 

Income tax expense

 

220

   

220

 

Depreciation and amortization expense

 

102,000

   

102,000

 

EBITDA

 

259,885

   

289,885

 

Loss on extinguishment of debt (1)

 

11,935

   

11,935

 

Share-based compensation expense (2)

 

28,000

   

28,000

 

Legal fees (3)

 

180

   

180

 

Adjusted EBITDA

 

$

300,000

   

$

330,000

 

Adjusted EBITDA margin

 

25

%

 

25

%

_________________________

(1)

Represents the loss on debt extinguishment related to the Initial Term Loan Facility.

(2)

Represents non-cash share-based compensation expense relating to equity awards.

(3)

Represents non-recurring legal fees unrelated to our core operations.

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gohealth-reports-second-quarter-2021-results-301353649.html

SOURCE GoHealth, Inc.

Our Awards